Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

Journal of the American Society of Nephrology

Volumn 16, Issue 3 SUPPL. 1, 2005, Pages

  Campese, Vito M ^a   Nadim, Mitra K ^a   Epstein, Murray ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; COLESTYRAMINE; CREATININE; CYCLOOXYGENASE 2; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; GAMMA INTERFERON; GLUCOSE; HISTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PRAVASTATIN; SIMVASTATIN; STATIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; INFLAMMATION; KIDNEY FUNCTION; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HOSPITALIZATION; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MALE; METABOLISM; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

CORONARY ARTERIOSCLEROSIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20844447308     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110958     Document Type: Conference Paper

References (82)

1. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41: S1-S91, 2003
2. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59: 407-414, 2001
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
4. Uhlig K, Levey AS, Sarnak MJ: Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 16: 118-127, 2003
5. Fellstrom BC, Holdaas H, Jardine AG: Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl 63: S204-S206, 2003
6. Campese VM, Bianchi S, Bigazzi R: Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int Suppl 71: S10-S13, 1999
7. Magil AB: Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol 12: 33-40, 1999
8. Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, Kodama T, Suzuki H, Maki S: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 43: 918-927, 1993
9. Rovin BH, Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43: 218-225, 1993
10. Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, Schlondorff D: Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 39: 858-866, 1991
11. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D: Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int 141: 1161-1169, 1992
12. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M: Effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. J Clin Pathol 57: 728-734, 2004
13. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF: Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 48: 363-371, 1995
14. Keane WF, O'Donnell MP, Kasiske BL, Kim Y: Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 4: 187-194, 1993
15. Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP: Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun 267: 536-540, 2000
16. Guijarro C, Kim Y, Schoonover CM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Kashtan CE: Lovastatin inhibits lipopolysaccharide-induced NF-κB activation in human mesangial cells. Nephrol Dial Transplant 11: 990-996, 1996
17. Chen HC, Guh JY, Shin SJ, Lai YH: Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 160: 141-146, 2002
18. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 52: 1016-1027, 1997
19. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998
20. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23: 58-63, 2003
21. Asberg A, Hartmann A, Fjeldsa E, Holdaas H: Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 16: 1920-1924, 2001
22. Yoshimura A, Nemoto T, Sugenoya Y, Inui K, Watanabe S, Inoue Y, Sharif S, Yokota N, Uda S, Morita H, Ideura T: Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int Suppl 71: S84-S87, 1999
23. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK: Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Renal Physiol 286: F46-F57, 2004
24. Yamashita T, Kawashima S, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M: A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 20: 2465-2473, 2002
25. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31: 190-194, 1998
26. Zhou M-S, Jaimes E, Raij L: In salt-sensitive hypertension, statins protect end-organ injury via increased NO production and decreased reactive oxygen species [Abstract]. Am J Hypertens 17: 18A, 2004
27. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int 58: 293-301, 2000
28. Manttari M, Tiula E, Alikoski T, Manninen V: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26: 670-675, 1995
29. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084-2091, 2003
30. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260-269, 2001
31. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39: 1213-1217, 2002
32. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30: 980-987, 2000
33. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-670, 2003
34. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7-22, 2002
35. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613, 2003
36. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297-304, 2002
37. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R: Atorvastatin and simvastatin in patients on hemodialysis: Effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 16: 238-244, 2003
38. Isoniemi H, Nurminen M, Tikkanen MJ, von Willebrand E, Krogerus L, Ahonen J, Eklund B, Hockerstedt K, Salmela K, Hayry P: Risk factors predicting chronic rejection of renal allografts. Transplantation 57: 68-72, 1994
39. McPherson R, Tsoukas C, Baines MG, Vost A, Melino MR, Zupkis RV, Pross HF: Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 13: 439-444, 1993
40. Chakrabarti R, Engleman EG: Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 266: 12216-12222, 1991
41. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621-627, 1995
42. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B: Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 96: 1398-1402, 1997
43. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Teraski PI: The effect of pravastatin on acute rejection after kidney transplantation-A pilot study. Transplantation 61: 1469-1474, 1996
44. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B: The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 72: 223-227, 2001
45. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL Study. Circulation 108: 1560-1566, 2003
46. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235, 1999
47. Nuotio K, Lindsberg PJ, Carpen O, Soinne L, Lehtonen-Smeds EM, Saimanen E, Lassila R, Sairanen T, Sarna S, Salonen O, Kovanen PT, Kaste M: Adhesion molecule expression in symptomatic and asymptomatic carotid stenosis. Neurology 60: 1890-1899, 2003
48. Blake GJ: Inflammatory biomarkers of the patient with myocardial insufficiency. Curr Opin Crit Care 9: 369-374, 2003
49. Diaz MN, Frei B, Vita JA, Keaney JF Jr: Antioxidants and atherosclerotic heart disease. N Engl J Med 337: 408-416, 1997
50. Mason JC: Statins and their role in vascular protection. Clin Sci (Lond) 105: 251-266, 2003
51. Crisby M: Modulation of the inflammatory process by statins. Drugs Today 39: 137-143, 2003
52. Pierre-Paul D, Gahtan V: Noncholesterol-lowering effects of statins. Vasc Endovascular Surg 37: 301-313, 2003
53. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Karas RH: Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med 139: 670-682, 2003
54. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 251: 338-347, 2002
55. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S: Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45: 147-154, 2002
56. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103: 1191-1193, 2001
57. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839-844, 1998
58. Vamvakopoulos JE, Green C: HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: A potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord 3: 6, 2003
59. Ridker PM: Inflammatory biomarkers, statins, and the risk of stroke: Cracking a clinical conundrum. Circulation 105: 2583-2585, 2002
60. Ridker PM: Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. Curr Cardiol Rep 2: 269-673, 2000
61. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23: 729-736, 2003
62. Stokes KY, Cooper D, Tailor A, Granger DN: Hypercholesterolemia promotes inflammation and microvascular dysfunction: Role of nitric oxide and superoxide. Free Radic Biol Med 33: 1026-1036, 2002
63. Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering-Are they clinically relevant? Eur Heart J 24: 225-248, 2003
64. Pfeilschifter J: Nitric oxide triggers the expression of proinflammatory and protective gene products in mesangial cells and the inflamed glomerulus. Nephrol Dial Transplant 17: 347-348, 2002
65. Zatz R, Fujihara CK: Mechanisms of progressive renal disease: Role of angiotensin II, cyclooxygenase products and nitric oxide. J Hypertens 20[Suppl 3]: S37-S44, 2002
66. Blantz RC, Munger K: Role of nitric oxide in inflammatory conditions. Nephron 90: 373-378, 2002
67. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J: Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147: 253-261, 1999
68. Rogler G, Lackner KJ, Schmitz G: Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol 76: 114A-116A, 1995
69. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, Numano F: HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 21: 1165-1171, 2001
70. Frenette PS: Locking a leukocyte integrin with statins. N Engl J Med 345: 1419-1421, 2001
71. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22: 300-305, 2002
72. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719, 1998
73. Walter MF, Jacob RF, Weng Y, Mason RP: Active hydroxy metabolite of atorvastatin increases resistance of human low-density lipoproteins to oxidative modification. Presented at the American College of Cardiology Conference, Chicago, IL, March 30-April 4, 2003
74. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S: Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 87: 616-622, 2000
75. Sukhova GK, Williams JK, Libby P: Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22: 1452-1458, 2002
76. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95: 1126-1131, 1997
77. de Man FH, Weverling-Rijnsburger AW, van der Laarse A, Smelt AH, Jukema JW, Blauw GJ: Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: Reversal after lipid-lowering therapy by atorvastatin. Arterioscler Thromb Vasc Biol 20: 744-750, 2000
78. Riesen WF, Engler H, Risch M, Korte W, Noseda G: Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23: 794-799, 2002
79. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933-1935, 2001
80. Gomez-Gerique JA, Ros E, Olivan J, Mostaza JM, Vilardell M, Pinto X, Civeira F, Hernandez A, da Silva PM, Rodriguez-Botaro A, Zambon D, Lima J, Diaz C, Aristegui R, Sol JM, Chaves J, Hernandez G; ATOMIX Investigators: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 162: 245-251, 2002
81. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C: Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166: 129-135, 2003
82. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291: 1071-1080, 2004